Low Anterior Resection Syndrome Clinical Trial
Official title:
Low Anterior Resection Syndrome: Retrograde Enema Program vs Medical Management
This clinical trial studies if a bowel management program with a retrograde rectal enema (RRE) for the treatment of low anterior resection syndrome (LARS) in rectal cancer patients is better than medical management alone. Rectal cancer treatment can include a procedure where part of the rectum with cancer is removed and the remaining part of the rectum is reconnected to the colon, this is called a low anterior resection of the rectum. LARS is a common condition that can develop after undergoing a low anterior resection of the rectum. LARS consists of any change in how the body performs defecation, the discharge of feces from the body, after undergoing a resection procedure. Patients with LARS may experience fecal urgency, incontinence, increased frequency, constipation, feelings of incomplete bowel movement, or bowel emptying difficulties. Patients may experience individual symptoms of LARS or a combination of them. A bowel management program assists patient's with identifying a specific bowel management regimen that works best for managing symptoms of LARS. A RRE consists of inserting a catheter through the anus into the rectum. The RRE is designed to assist fecal emptying. Medical management of LARS can include the use of fiber, loperamide hydrochloride, or pelvic floor physical therapy. Fiber may help relieve constipation, feelings of incomplete bowel movement, or bowel emptying difficulties. Loperamide hydrocholoride may help lessen fecal urgency, incontinence, or increased frequency. Pelvic floor physical therapy may help restore strength in the rectum possibly helping to improve symptoms of LARS. Participating in a bowel management program with a RRE may be more effective in treating LARS than medical management alone.
Status | Not yet recruiting |
Enrollment | 80 |
Est. completion date | December 31, 2026 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age = 18 years old - LARS diagnosis - Patients with history of rectal cancer Exclusion Criteria: - Patients presenting with significant stricture that need a definitive surgical management strategy; patients with minor or clinically negligible strictures can still be candidates. Patients who are able to pass the catheter and the balloon per rectum may be candidates after a digital rectal exam at their initial visit - Patients with any chemo or radiation therapy in the last 6 months - Patients who currently have colorectal cancer - Patients with recurrent colorectal cancer - Patients who have undergone a colorectal surgical procedure within the last three months - Patients < 18 years old - Active sacral nerve simulator - Altered mental status or mental disability that would alter ability to self-administer enema - Any reason the research team believes the subject is not an appropriate candidate for this study (i.e., transportation issues, history of no-show appointments, lack of reliable communications, vulnerable population(s), etc.) |
Country | Name | City | State |
---|---|---|---|
United States | Ohio State University Comprehensive Cancer Center | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
Ohio State University Comprehensive Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Fecal incontinence | Will be measured using a validated scoring tool for LARS (Memorial Sloan Kettering Cancer Center Bowel Function Instrument Questionnaire [MSKCC BFI]). Effect size (Cohen's d > 0.80) will be computed to ensure the effect of findings. P < 0.05 is considered significant. Statistical analysis will be conducted using linear or nonlinear mixed modelling as found appropriate by the statistician. | Up to 1 year from start of treatment | |
Primary | Effectiveness assessed using LARS validated scoring tool | Will be assessed using LARS validated scoring tool. Effect size (Cohen's d > 0.80) will be computed to ensure the effect of findings. P < 0.05 is considered significant. Statistical analysis will be conducted using linear or nonlinear mixed modelling as found appropriate by the statistician. | Up to 1 year from start of treatment | |
Secondary | Feasibility measured by Patient Satisfaction Survey | Will be assessed by administering a patient satisfaction survey post treatment. Effect size (Cohen's d > 0.80) will be computed to ensure the effect of findings. P < 0.05 is considered significant. Statistical analysis will be conducted using linear or nonlinear mixed modelling as found appropriate by the statistician. | At 1 year from start of treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04087421 -
Comparison of Transanal Irrigation and Glycerol Suppositories in Treatment of Low Anterior Resection Syndrome
|
Phase 3 | |
Recruiting |
NCT03828318 -
Impact of a Patient-Centered Program for Low Anterior Resection Syndrome A Multicenter Randomized Controlled Trial
|
N/A | |
Recruiting |
NCT04023448 -
The Effect of Different Reconstruction Methods on Anterior Resection Syndrome
|
N/A | |
Recruiting |
NCT04040842 -
International Low Anterior Resection Score Evaluation
|
||
Completed |
NCT05605600 -
Translation of the International Consensus Definition of LARS Into a Bowl Dysfunction Severity Scoring Tool (New LARS Score)
|
||
Completed |
NCT05016583 -
Paula Method of Exercises in Patients With LARS Syndrome
|
N/A | |
Active, not recruiting |
NCT05042700 -
The Effect of Melatonin in Patients With Low Anterior Resection Syndrome
|
Phase 2 | |
Recruiting |
NCT04612569 -
Feasibility and Impact of a Prehabilitation and Rehabilitation Program for the Continuity of Care in Severe Low Anterior Resection Syndrome.
|
||
Completed |
NCT04896879 -
Experiences and Needs of Patients, Their Informal Caregiver and Healthcare Professionals Regarding LARS
|
||
Recruiting |
NCT06162143 -
Effect of Gelsectan® in the Treatment of Low Anterior Resection Syndrome
|
||
Withdrawn |
NCT03257332 -
Determining Early Development of Faecal Incontinence and Anorectal Muscle Function After Surgery for Rectal Cancer.
|
||
Completed |
NCT03916549 -
Acupuncture in Low Anterior Resection Syndrome Treatment
|
Phase 1 | |
Completed |
NCT05020132 -
Bowel Dysfunction After Rectal Cancer Treatment
|
||
Completed |
NCT03598231 -
Effectiveness of Sacral Neuromodulation in Low Anterior Resection Syndrome
|
N/A | |
Recruiting |
NCT05420870 -
Effect of Exercise on Bowel Function in Colorectal Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT05319054 -
Pathway of Low Anterior Resection Syndrome Relief After Surgery: a Feasibility Study
|
N/A | |
Completed |
NCT01589471 -
The Value of Botox-A for Management of Low Anterior Resection Syndrome
|
Phase 2 | |
Completed |
NCT03215017 -
Effect of Treatment of Low Anterior Resection Syndrome After Rectal Cancer Surgery
|
N/A | |
Completed |
NCT05129215 -
Development and Validation of The Post-RT LARS Prediction Model (PORTLARS)
|
||
Recruiting |
NCT05682157 -
Paula Method of Exercises in Patients With LARS Syndrome:Randomized Controlled Trial
|
N/A |